BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells

Myeloproliferative Neoplasms with myelofibrosis (MPN-MF) demonstrate constitutive activation of JAK-STAT signaling, which responds to treatment with the JAK1 & 2 kinase inhibitor (JAKi) ruxolitinib. However, MPN-MF often progresses (~20%) to secondary AML (sAML), where standard induction chemoth...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leukemia
Main Authors: Saenz, Dyana T., Fiskus, Warren, Manshouri, Taghi, Rajapakshe, Kimal, Krieger, Stephanie, Sun, Baohua, Mill, Christopher P., DiNardo, Courtney, Pemmaraju, Naveen, Kadia, Tapan, Parmar, Simrit, Sharma, Sunil, Coarfa, Cristian, Qiu, Peng, Verstovsek, Srdan, Bhalla, Kapil N.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5345582/
https://ncbi.nlm.nih.gov/pubmed/27677740
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2016.260
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados